Alumni raised $1.45B in 2022 - Download Free Report Now

Humacyte (NASDAQ:HUMA)

Human-based tissue scaffolds, including a biological vascular graft to provide vascular access to end-stage renal disease patients who need hemodialys....

Start Trial Get Full Profile

There’s no risk. Start your trial today to see profiles of Humacyte (NASDAQ:HUMA) plus 5517 other startups.

Start Free 7 Day Trial Now

Learn More About Humacyte (NASDAQ:HUMA)

Technology/product details

Potential acquirers

Revenue projections

Capital raised to date

Growth strategy

Market landscape

Competing Startups


Companies We Work With